Pharnext SA (ALPHA.PA)

0.0045 €

+0.00 (+36.36%)
Rating:
Recommendation:
-
Symbol ALPHA.PA
Price 0.0045 €
Beta 2.864
Volume Avg. 63.88M
Market Cap 0.592M
Shares () -
52 Week Range 0.0014-1.04
1y Target Est -
DCF Unlevered ALPHA.PA DCF ->
DCF Levered ALPHA.PA LDCF ->
ROE 197.08% Strong Buy
ROA -138.66% Strong Sell
Operating Margin -
Debt / Equity -192.13% Sell
P/E -
P/B -0 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Daniel Cohen
Healthcare
Biotechnology
Paris

Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.